CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Local senolysis in aged mice only partially replicates the benefits of systemic senolysis

Open access

Abstract

Clearance of senescent cells (SnCs) can prevent several age-related pathologies, including bone loss. However, the local versus systemic roles of SnCs in mediating tissue dysfunction remain unclear. Thus, we developed a mouse model (p16-LOX-ATTAC) that allowed for inducible SnC elimination (senolysis) in a cell-specific manner and compared the effects of local versus systemic senolysis during aging using bone as a prototype tissue. Specific removal of Sn osteocytes prevented age-related bone loss at the spine, but not the femur, by improving bone formation without affecting osteoclasts or marrow adipocytes. By contrast, systemic senolysis prevented bone loss at the spine and femur and not only improved bone formation, but also reduced osteoclast and marrow adipocyte numbers. Transplantation of SnCs into the peritoneal cavity of young mice caused bone loss and also induced senescence in distant host osteocytes. Collectively, our findings provide proof-of-concept evidence that local senolysis has health benefits in the context of aging, but, importantly, that local senolysis only partially replicates the benefits of systemic senolysis. Furthermore, we establish that SnCs, through their senescence-associated secretory phenotype (SASP), lead to senescence in distant cells. Therefore, our study indicates that optimizing senolytic drugs may require systemic instead of local SnC targeting to extend healthy aging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci162519

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Sn osteocytes accumulate in bone with aging and are cleared by AP treatment in old DMP1-Cre+/– p16-LOX-ATTAC mice. (A) Changes in female (pink bars) and male (blue bars) murine p16Ink4a mRNA expression throughout life in osteocyte-enriched bone from C57BL/6 WT mice, relative to young adult (6-month-old) mice. ***P < 0.001, by ANOVA with Tukey’s post hoc test. (B) Representative images of a non-Sn osteocyte (original magnification, ×63 oil) in a young (6-month-old) mouse versus a Sn osteocyte in an old (24-month-old) mouse according to the TAF (white arrows) assay (n = 8 females/group). Scale bars: 20 μm and 2 μm (enlarged insets). (C–E) Quantification of (C) the mean TAF/osteocyte and (D) the mean percentage of TAF+ osteocytes/mouse based on: the percentage of osteocytes with 1 or more TAF, the percentage of osteocytes with 2 or more TAF, and the percentage of osteocytes with 3 or more TAF, respectively; and quantification of (E) the mean percentage of 3 or more TAF+ osteocytes/mouse (n = 8 females/group). (F) Schematic of the unrecombined p16-LOX-ATTAC construct and cross with DMP1-Cre mice. (G) Study design for local clearance of Sn osteocytes in old (20 months) p16-LOX-ATTAC x DMP1-Cre mouse cohorts, males and females combined, randomized to Veh (gray) or AP (teal) treatment for 4 months. (H) RT-qPCR analysis of p16Ink4a mRNA expression across tissues in mice (males and females combined, n = 12–18 per tissue) treated with Veh (gray) or AP (teal). (I and J) Quantification of (I) the mean percentage of TAF+ osteocytes/mouse and (J) the mean percentage of TAF+ osteoblasts per mouse (OBs/mouse) based on the percentage of cells with 1 or more TAF, the percentage of cells with 2 or more TAF, and the percentage of cells with 3 or more TAF, respectively. (K) Representative images of perigonadal adipose tissue staining for SA–β-Gal+ cells in Veh- and AP-treated mice. Scale bars: 100 μm. (L) Quantification of SA–β-Gal+ adipocytes in mice treated with Veh (gray, n = 9: n = 5 females, n = 4 males) or AP (teal, n = 11: n = 6 females, n = 5 males). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate. OCY, osteocytes.
Figure 1 Sn osteocytes accumulate in bone with aging and are cleared by AP treatment in old DMP1-Cre+/– p16-LOX-ATTAC mice. (A) Changes in female (pink bars) and male (blue bars) murine p16Ink4a mRNA expression throughout life in osteocyte-enriched bone from C57BL/6 WT mice, relative to young adult (6-month-old) mice. ***P < 0.001, by ANOVA with Tukey’s post hoc test. (B) Representative images of a non-Sn osteocyte (original magnification, ×63 oil) in a young (6-month-old) mouse versus a Sn osteocyte in an old (24-month-old) mouse according to the TAF (white arrows) assay (n = 8 females/group). Scale bars: 20 μm and 2 μm (enlarged insets). (C–E) Quantification of (C) the mean TAF/osteocyte and (D) the mean percentage of TAF+ osteocytes/mouse based on: the percentage of osteocytes with 1 or more TAF, the percentage of osteocytes with 2 or more TAF, and the percentage of osteocytes with 3 or more TAF, respectively; and quantification of (E) the mean percentage of 3 or more TAF+ osteocytes/mouse (n = 8 females/group). (F) Schematic of the unrecombined p16-LOX-ATTAC construct and cross with DMP1-Cre mice. (G) Study design for local clearance of Sn osteocytes in old (20 months) p16-LOX-ATTAC x DMP1-Cre mouse cohorts, males and females combined, randomized to Veh (gray) or AP (teal) treatment for 4 months. (H) RT-qPCR analysis of p16Ink4a mRNA expression across tissues in mice (males and females combined, n = 12–18 per tissue) treated with Veh (gray) or AP (teal). (I and J) Quantification of (I) the mean percentage of TAF+ osteocytes/mouse and (J) the mean percentage of TAF+ osteoblasts per mouse (OBs/mouse) based on the percentage of cells with 1 or more TAF, the percentage of cells with 2 or more TAF, and the percentage of cells with 3 or more TAF, respectively. (K) Representative images of perigonadal adipose tissue staining for SA–β-Gal+ cells in Veh- and AP-treated mice. Scale bars: 100 μm. (L) Quantification of SA–β-Gal+ adipocytes in mice treated with Veh (gray, n = 9: n = 5 females, n = 4 males) or AP (teal, n = 11: n = 6 females, n = 5 males). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate. OCY, osteocytes.CC BY · PubMed Central
Figure 2 Effects of local Sn osteocyte–specific clearance on the skeleton of old female and male mice. (A) Study design for local clearance of Sn osteocytes in female old (20 months) DMP1-Cre+/– p16-LOX-ATTAC mice randomized to Veh (pink) or AP (red) treatment for 4 months. (B) DXA-derived aBMD (g/cm2) at baseline in 20-month-old females (n = 6 females/group). (C) Quantification of the study endpoint (24 months) μCT-derived bone volume BV/TV fraction at the lumbar spine in mice treated with Veh (n = 15 females) versus AP (n = 15 females). (D–H) Quantification of μCT-derived (D) BV/TV, (E) cortical thickness (Ct.Th), (F) endocortical circumference (EC), (G) periosteal circumference (PC), and (H) μFEA-derived failure load at the femur metaphysis in female mice (n = 15 females/group). (I) Study design for local clearance of Sn osteocytes in old (20 months) male DMP1-Cre+/– p16-LOX-ATTAC mice randomized to Veh (light blue) or AP (dark blue) treatment for 4 months. (J) DXA-derived aBMD (g/cm2) at baseline in 20-month-old male mice (n = 5/males group). (K) Quantification of the study endpoint (24 months) μCT-derived BV/TV at the lumbar spine in male mice treated with Veh (n = 10 males) or AP (n = 10 males). (L–P) Quantification of μCT-derived (L) BV/TV, (M) cortical thickness, (N) endocortical circumference, (O) periosteal circumference, and (P) μFEA-derived failure load at the femur metaphysis in male mice (n = 10/group). Data represent the mean ± SEM. NS, P > 0.05; *P < 0.05 and **P < 0.01, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.
Figure 2 Effects of local Sn osteocyte–specific clearance on the skeleton of old female and male mice. (A) Study design for local clearance of Sn osteocytes in female old (20 months) DMP1-Cre+/– p16-LOX-ATTAC mice randomized to Veh (pink) or AP (red) treatment for 4 months. (B) DXA-derived aBMD (g/cm2) at baseline in 20-month-old females (n = 6 females/group). (C) Quantification of the study endpoint (24 months) μCT-derived bone volume BV/TV fraction at the lumbar spine in mice treated with Veh (n = 15 females) versus AP (n = 15 females). (D–H) Quantification of μCT-derived (D) BV/TV, (E) cortical thickness (Ct.Th), (F) endocortical circumference (EC), (G) periosteal circumference (PC), and (H) μFEA-derived failure load at the femur metaphysis in female mice (n = 15 females/group). (I) Study design for local clearance of Sn osteocytes in old (20 months) male DMP1-Cre+/– p16-LOX-ATTAC mice randomized to Veh (light blue) or AP (dark blue) treatment for 4 months. (J) DXA-derived aBMD (g/cm2) at baseline in 20-month-old male mice (n = 5/males group). (K) Quantification of the study endpoint (24 months) μCT-derived BV/TV at the lumbar spine in male mice treated with Veh (n = 10 males) or AP (n = 10 males). (L–P) Quantification of μCT-derived (L) BV/TV, (M) cortical thickness, (N) endocortical circumference, (O) periosteal circumference, and (P) μFEA-derived failure load at the femur metaphysis in male mice (n = 10/group). Data represent the mean ± SEM. NS, P > 0.05; *P < 0.05 and **P < 0.01, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.CC BY · PubMed Central
Figure 3 Effects of local Sn osteocyte–specific clearance on the skeleton of old mice. (A) Study design in old (20 months) DMP1-Cre+/– p16-LOX-ATTAC mice, males and females combined, randomized to Veh (gray) or AP (teal). (B) DXA-derived aBMD (g/cm2) at baseline (20 months; n = 11/group: n = 6 females, n = 5 males per group). (C) Endpoint lumbar spine μCT-derived bone volume fraction (BV/TV; %) in Veh-treated (n = 25; n = 15 females, n = 10 males) versus AP-treated (n = 25: n = 15 females, n = 10 males) mice. (D) Representative spine μCT images of Veh- versus AP-treated mice. (E) Lumbar spine μFEA-derived failure load in Veh-treated mice (n = 25: n = 15 females, n = 10 males) versus AP-treated (n = 25: n = 15 females, n = 10 males). (F) Lumbar spine BFR per bone surface (BFR/BS) (μm3/μm2/d; n = 11/group: n = 6 females, n = 5 males per group). (G) Lumbar spine representative images of Alizarin red and calcein fluorochrome dynamic BFR labels on trabecular surfaces in Veh- and AP-treated mice. Scale bars: 10 μm. (H and I) Lumbar spine histomorphometric quantification (n = 8/group: n = 4 females, n = 4 males per group) of (H) osteoclast numbers per bone perimeter (N.Oc/B.Pm/mm) and (I) osteoblast numbers per bone perimeter (N.Ob/B.Pm/mm). (J–N) Femur metaphysis μCT-derived (J) BV/TV, (K) cortical thickness, (L) endocortical circumference, (M) periosteal circumference, and (N) μFEA-derived failure load (n = 25/group: n = 15 females, n = 10 males per group). (O) Femur histomorphometric quantification (n = 8/group: n = 4 females, n = 4 males per group) of periosteal cortical (Pc.) BFR/BS (μm3/μm2/d). (P) Representative images of Alizarin red and calcein fluorochrome dynamic BFR labeling on periosteal cortical surfaces of femurs from Veh- and AP-treated mice. Scale bars: 10 μm. (Q–T) Femur histomorphometric quantification (n = 8/group: n = 4 females, n = 4 males per group) of (Q) endocortical (Ec.) BFR/BS (μm3/μm2/d), (R) endocortical N.Oc/B.Pm (/mm), (S) endocortical N.Ob/B.Pm (/mm), and (T) bone marrow adipocyte numbers. Data represent the mean ± SEM. NS, P > 0.05; *P < 0.05 and **P < 0.01, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.
Figure 3 Effects of local Sn osteocyte–specific clearance on the skeleton of old mice. (A) Study design in old (20 months) DMP1-Cre+/– p16-LOX-ATTAC mice, males and females combined, randomized to Veh (gray) or AP (teal). (B) DXA-derived aBMD (g/cm2) at baseline (20 months; n = 11/group: n = 6 females, n = 5 males per group). (C) Endpoint lumbar spine μCT-derived bone volume fraction (BV/TV; %) in Veh-treated (n = 25; n = 15 females, n = 10 males) versus AP-treated (n = 25: n = 15 females, n = 10 males) mice. (D) Representative spine μCT images of Veh- versus AP-treated mice. (E) Lumbar spine μFEA-derived failure load in Veh-treated mice (n = 25: n = 15 females, n = 10 males) versus AP-treated (n = 25: n = 15 females, n = 10 males). (F) Lumbar spine BFR per bone surface (BFR/BS) (μm3/μm2/d; n = 11/group: n = 6 females, n = 5 males per group). (G) Lumbar spine representative images of Alizarin red and calcein fluorochrome dynamic BFR labels on trabecular surfaces in Veh- and AP-treated mice. Scale bars: 10 μm. (H and I) Lumbar spine histomorphometric quantification (n = 8/group: n = 4 females, n = 4 males per group) of (H) osteoclast numbers per bone perimeter (N.Oc/B.Pm/mm) and (I) osteoblast numbers per bone perimeter (N.Ob/B.Pm/mm). (J–N) Femur metaphysis μCT-derived (J) BV/TV, (K) cortical thickness, (L) endocortical circumference, (M) periosteal circumference, and (N) μFEA-derived failure load (n = 25/group: n = 15 females, n = 10 males per group). (O) Femur histomorphometric quantification (n = 8/group: n = 4 females, n = 4 males per group) of periosteal cortical (Pc.) BFR/BS (μm3/μm2/d). (P) Representative images of Alizarin red and calcein fluorochrome dynamic BFR labeling on periosteal cortical surfaces of femurs from Veh- and AP-treated mice. Scale bars: 10 μm. (Q–T) Femur histomorphometric quantification (n = 8/group: n = 4 females, n = 4 males per group) of (Q) endocortical (Ec.) BFR/BS (μm3/μm2/d), (R) endocortical N.Oc/B.Pm (/mm), (S) endocortical N.Ob/B.Pm (/mm), and (T) bone marrow adipocyte numbers. Data represent the mean ± SEM. NS, P > 0.05; *P < 0.05 and **P < 0.01, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.CC BY · PubMed Central
Figure 4 Effects of local Sn osteocyte clearance on empty lacunae, osteocyte apoptosis, and osteocyte LCN quality. (A) Study design for the local clearance of Sn osteocytes in old (20 months) DMP1-Cre+/– p16-LOX-ATTAC mouse cohorts, males and females combined, randomized to Veh (gray) or AP (teal) treatment for 4 months. (B–D) Study endpoint (24 months) quantification of (B) total osteocytes per bone area and (C) percentage of osteocyte empty lacunae in mice treated with Veh (n = 8: n = 4 females, n = 4 males) versus AP (n = 8: n = 4 females, n = 4 males), and (D) representative images of osteocyte empty lacunae (arrowheads). Scale bar: 25 μm. (E–G) Quantification of osteocyte apoptosis, including (E) total numbers of osteocytes analyzed and (F) percentage of osteocyte apoptosis in mice treated with Veh (n = 8: n = 4 females, n = 4 males) versus AP (n = 8: n = 4 females, n = 4 males), and (G) representative images of DAPI-stained, TUNEL+, and merged apoptotic osteocytes. Scale bars: 25 μm. (H) Quantification of osteocyte LCN score for mice treated with Veh (n = 9: n = 5 females, n = 4 males) versus AP (n = 5: n = 3 females, n = 2 males), and (I) representative images of DAPI-stained, phalloidin-stained, and merged osteocyte LCNs. Scale bars: 25 μm. Data represent the mean ± SEM. NS, P > 0.05; *P < 0.05, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.
Figure 4 Effects of local Sn osteocyte clearance on empty lacunae, osteocyte apoptosis, and osteocyte LCN quality. (A) Study design for the local clearance of Sn osteocytes in old (20 months) DMP1-Cre+/– p16-LOX-ATTAC mouse cohorts, males and females combined, randomized to Veh (gray) or AP (teal) treatment for 4 months. (B–D) Study endpoint (24 months) quantification of (B) total osteocytes per bone area and (C) percentage of osteocyte empty lacunae in mice treated with Veh (n = 8: n = 4 females, n = 4 males) versus AP (n = 8: n = 4 females, n = 4 males), and (D) representative images of osteocyte empty lacunae (arrowheads). Scale bar: 25 μm. (E–G) Quantification of osteocyte apoptosis, including (E) total numbers of osteocytes analyzed and (F) percentage of osteocyte apoptosis in mice treated with Veh (n = 8: n = 4 females, n = 4 males) versus AP (n = 8: n = 4 females, n = 4 males), and (G) representative images of DAPI-stained, TUNEL+, and merged apoptotic osteocytes. Scale bars: 25 μm. (H) Quantification of osteocyte LCN score for mice treated with Veh (n = 9: n = 5 females, n = 4 males) versus AP (n = 5: n = 3 females, n = 2 males), and (I) representative images of DAPI-stained, phalloidin-stained, and merged osteocyte LCNs. Scale bars: 25 μm. Data represent the mean ± SEM. NS, P > 0.05; *P < 0.05, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.CC BY · PubMed Central
Figure 5 Changes in SenMayo genes and regulators of bone remodeling in response to local osteocyte-specific versus systemic SnC clearance. (A and B) After 2 weeks, a comparison of the 2 AP-treated groups (INK versus DMP) revealed broader downregulation of SASP- and Sn-related genes in the systemic SnC clearance model (INK) versus the local osteocyte-specific model (DMP). (C) BioPlanet 2019 pathway analysis emphasized the senescence and autophagy as well as the p53/Il2/Egf pathways as being regulated in the INK model, whereas the Wnt/Lrp6/IL10/IL4 pathways were regulated in the DMP model. (D and E) Changes in mRNA expression of (D) Sost (encoding sclerostin) and (E) Rankl (also known as Tnfsf11) in response to systemic (INK) versus local osteocyte-specific (DMP) senolysis (INK Veh n = 15, INK AP n = 15; DMP Veh n = 15, DMP AP n = 15). NS, P > 0.05; **P < 0.01, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.
Figure 5 Changes in SenMayo genes and regulators of bone remodeling in response to local osteocyte-specific versus systemic SnC clearance. (A and B) After 2 weeks, a comparison of the 2 AP-treated groups (INK versus DMP) revealed broader downregulation of SASP- and Sn-related genes in the systemic SnC clearance model (INK) versus the local osteocyte-specific model (DMP). (C) BioPlanet 2019 pathway analysis emphasized the senescence and autophagy as well as the p53/Il2/Egf pathways as being regulated in the INK model, whereas the Wnt/Lrp6/IL10/IL4 pathways were regulated in the DMP model. (D and E) Changes in mRNA expression of (D) Sost (encoding sclerostin) and (E) Rankl (also known as Tnfsf11) in response to systemic (INK) versus local osteocyte-specific (DMP) senolysis (INK Veh n = 15, INK AP n = 15; DMP Veh n = 15, DMP AP n = 15). NS, P > 0.05; **P < 0.01, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.CC BY · PubMed Central
Figure 6 Transplantation of cells made Sn by IR causes skeletal aging in young adult mice. (A) Confirmation of cellular senescence 20 days after 10 Gy IR using SA–β-Gal staining. Scale bar: 25 μm. (B) RT-qPCR analysis of p16Ink4a and p21Cip1 mRNA expression in Sn versus control fibroblasts 20 days after 10 Gy IR. (C) Study design for control and Sn cell transplantation (via i.p. injection) and skeletal phenotyping in young adult male C57BL/6 WT mice (n = 11 males/group). (D–F) Quantification of μCT-derived (D) lumbar spine BV/TV fraction, (E) femur metaphysis cortical thickness, and (F) femur metaphysis μFEA-derived failure load (i.e., bone strength) in mice transplanted with control (n = 11 males) versus Sn (n = 11 males) cells. (G and H) Quantification of circulating serum bone turnover markers, including (G) the bone formation marker P1NP (ng/mL) and (H) the bone resorption marker cross-linked CTx (ng/mL) (n = 11 males/group). (I–L) Histomorphometric quantification at the femoral endocortical surface of (I) osteoblast numbers per bone perimeter (/mm), (J) mineral apposition rate (MAR) (μm/d), (K) BFR/BS (μm3/μm2/d), and (L) osteoclast numbers per bone perimeter (/mm) (n = 8 males/group). (M and N) Histomorphometric quantification of femur bone marrow (M) adipocyte numbers and (N) adipocyte perimeter (mm) (n = 8 males/group). (O and P) Quantification of (P) the mean percentage of TAF+ osteocytes per mouse and (P) the mean percentage of TAF+ osteoblasts per mouse based on the following criteria: the percentage of cells with 1 or more TAF, the percentage of cells with 2 or more TAF, and the percentage of cells with 3 or more TAF, respectively. Data represent the mean ± SEM. NS, P > 0.05; *P < 0.05, **P < 0.01, and ***P < 0.001, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.
Figure 6 Transplantation of cells made Sn by IR causes skeletal aging in young adult mice. (A) Confirmation of cellular senescence 20 days after 10 Gy IR using SA–β-Gal staining. Scale bar: 25 μm. (B) RT-qPCR analysis of p16Ink4a and p21Cip1 mRNA expression in Sn versus control fibroblasts 20 days after 10 Gy IR. (C) Study design for control and Sn cell transplantation (via i.p. injection) and skeletal phenotyping in young adult male C57BL/6 WT mice (n = 11 males/group). (D–F) Quantification of μCT-derived (D) lumbar spine BV/TV fraction, (E) femur metaphysis cortical thickness, and (F) femur metaphysis μFEA-derived failure load (i.e., bone strength) in mice transplanted with control (n = 11 males) versus Sn (n = 11 males) cells. (G and H) Quantification of circulating serum bone turnover markers, including (G) the bone formation marker P1NP (ng/mL) and (H) the bone resorption marker cross-linked CTx (ng/mL) (n = 11 males/group). (I–L) Histomorphometric quantification at the femoral endocortical surface of (I) osteoblast numbers per bone perimeter (/mm), (J) mineral apposition rate (MAR) (μm/d), (K) BFR/BS (μm3/μm2/d), and (L) osteoclast numbers per bone perimeter (/mm) (n = 8 males/group). (M and N) Histomorphometric quantification of femur bone marrow (M) adipocyte numbers and (N) adipocyte perimeter (mm) (n = 8 males/group). (O and P) Quantification of (P) the mean percentage of TAF+ osteocytes per mouse and (P) the mean percentage of TAF+ osteoblasts per mouse based on the following criteria: the percentage of cells with 1 or more TAF, the percentage of cells with 2 or more TAF, and the percentage of cells with 3 or more TAF, respectively. Data represent the mean ± SEM. NS, P > 0.05; *P < 0.05, **P < 0.01, and ***P < 0.001, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.CC BY · PubMed Central
Figure 7 The SASP impairs bone formation and enhances bone marrow adipogenesis. (A) Schematic of in vitro cellular senescence induction using 10 Gy IR and generation of CM following 20 days in culture. (B) Study design depicting the treatment of BMSCs with 20% control CM (CCM) or Sn CM (SCM) for 14 days. (C) Mineralization of BMSCs exposed to control CM or Sn CM at days 0, 7 (n = 6/group), and 14 (n = 6/group). (D) Quantification of eluted Alizarin red dye from BMSCs exposed to control CM or Sn CM at days 0, 7 (n = 6/group), and 14 (n = 6/group). (E) Representative images of APh staining of BMSCs exposed to control CM or Sn CM on day 7. (F) Changes in mRNA expression of osteoblastic genes in BMSCs exposed to either control CM (n = 6) or Sn CM (n = 6). (G) Representative images of Oil Red O staining of BMSCs exposed to either control CM or Sn CM. Scale bars: 25 μm. (H) Changes in mRNA expression of adipogenic genes in BMSCs exposed to either control CM or Sn CM (n = 6/group). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.
Figure 7 The SASP impairs bone formation and enhances bone marrow adipogenesis. (A) Schematic of in vitro cellular senescence induction using 10 Gy IR and generation of CM following 20 days in culture. (B) Study design depicting the treatment of BMSCs with 20% control CM (CCM) or Sn CM (SCM) for 14 days. (C) Mineralization of BMSCs exposed to control CM or Sn CM at days 0, 7 (n = 6/group), and 14 (n = 6/group). (D) Quantification of eluted Alizarin red dye from BMSCs exposed to control CM or Sn CM at days 0, 7 (n = 6/group), and 14 (n = 6/group). (E) Representative images of APh staining of BMSCs exposed to control CM or Sn CM on day 7. (F) Changes in mRNA expression of osteoblastic genes in BMSCs exposed to either control CM (n = 6) or Sn CM (n = 6). (G) Representative images of Oil Red O staining of BMSCs exposed to either control CM or Sn CM. Scale bars: 25 μm. (H) Changes in mRNA expression of adipogenic genes in BMSCs exposed to either control CM or Sn CM (n = 6/group). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by independent samples Student’s t test or Wilcoxon rank-sum test, as appropriate.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 81

Metadata

Authors
Farr, J. N., Saul, D., Doolittle, M. L., Kaur, J., Rowsey, J. L., Vos, S. J., Froemming, M. N., Lagnado, A. B., Zhu, Y., Weivoda, M., Ikeno, Y., Pignolo, R. J., Niedernhofer, L. J., Robbins, P. D., Jurk, D., Passos, J. F., LeBrasseur, N. K., Tchkonia, T., Kirkland, J. L., Monroe, D. G., & Khosla, S.
Affiliations
  • Mayo Clinic (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • University of Minnesota (US)
Corresponding author
  • Farr, Joshua N.
  • Khosla, Sundeep
Venue
Journal of Clinical Investigation
Published
2023-04-17
Volume
133
Issue
8
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4321445705
Cited by
81
References
54
Citations by year
2026: 26 · 2025: 15 · 2024: 28 · 2023: 12
FWCI
14.30
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute on Aging (AG062413,AG076515,AG068048,AG013925,AG063543,AG056278,AG063707)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK128552)
  • National Cancer Institute (UG3CA26810)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
senolysis, senescent cells, aging, age-related bone loss, osteocytes, senescence-associated secretory phenotype, osteoclasts, bone formation, senolytics, healthy aging
MeSH terms
Aging, Animals, Bone and Bones, Osteoclasts, Osteocytes, Cellular Senescence, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Local senolysis in aged mice only partially replicates the benefits of systemic senolysis. https://app.cochat.ai/papers/10.1172/jci162519
The paper
Farr, J. N., Saul, D., Doolittle, M. L., Kaur, J., Rowsey, J. L., Vos, S. J., Froemming, M. N., Lagnado, A. B., Zhu, Y., Weivoda, M., Ikeno, Y., Pignolo, R. J., Niedernhofer, L. J., Robbins, P. D., Jurk, D., Passos, J. F., LeBrasseur, N. K., Tchkonia, T., Kirkland, J. L., . . . Khosla, S. (2023). Local senolysis in aged mice only partially replicates the benefits of systemic senolysis. Journal of Clinical Investigation. https://doi.org/10.1172/jci162519

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.